Stock Analiz

Starling Oncology, Inc. STLN

Medical/Nursing Services · IPO 2020 · data as of November 13, 2026

$3.50Market cap $357M
Open the interactive analysis →

Starling Oncology, Inc. (STLN) is a healthcare company listed in the US with a market value of about $357M. In the twelve months to September 30, 2026 it had revenue of $620M and net income of -$30M, a net margin of -4.8%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is financial health (1/5).

Key numbers: a price to free cash flow of 19.0, 5-year revenue growth of 22% a year, a 5-year average ROIC of -37%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 131% above the current price.

About Starling Oncology

Starling Oncology is listed in the US and classified in medical/nursing services, IPO year 2020. Revenue went from $188M in 2020 to $503M in 2025, growth of about 21.8% a year. It was profitable in 1 of the last 6 years in our data. Its share count rose by 15% over three years (dilution for shareholders).

Score: 2.0 / 5

Value2/5
Future growth4/5
Track record2/5
Financial health1/5
Shareholder returns1/5

Checks passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity

Valuation

P/E (TTM)—
Forward P/E—
P/FCF19.0
P/S0.6
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield5.3%
Shareholder yield0.0%
Intrinsic value vs. price+131%

Growth and quality

Revenue growth (1 yr)27.8%
Revenue growth (5 yrs, per year)21.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11.9%
ROIC (5-yr avg.)-36.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$620M$503M$393M$324M$252M$203M$188M
Net income-$30M-$61M-$65M-$83M$152000-$11M-$14M
Free cash flow$19M-$28M-$30M-$41M-$67M-$36M-$686000
EPS (diluted)$-0.28$-0.54$-0.71$-0.92$-0.21$-0.16$-0.24
Net margin-4.8%-12.1%-16.4%-25.6%0.1%-5.4%-7.6%
ROIC—-37.3%-41.9%-38.5%-24.8%-41.4%-19.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $9.25, 164% above the current price; targets range from $8.00 to $10.00; the consensus rating is “Strong buy”; expected EPS is $-0.27 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Starling Oncology stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 131% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Starling Oncology pay a dividend?

Not currently.

Is Starling Oncology a good stock to buy?

We do not give buy or sell advice. Starling Oncology scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.